X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
IMC-1 (famciclovir) is a fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. It is being investegated for the treatment of fibromyalgia.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
IMC-1 (famciclovir) is a fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. It is being investegated for the treatment of fibromyalgia.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2023
Details:
IMC-1 (Famciclovir) is a fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. IMC-1 has been granted fast track designation by the FDA.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
The Company intends to use the net proceeds from the offering primarily to further advance the clinical development of IMC-1 (famciclovir) and for working capital and general corporate purposes.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering September 22, 2022
Details:
The Company intends to use the net proceeds from the offering primarily to further advance the clinical development of IMC-1 (famciclovir) and for working capital and general corporate purposes.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 19, 2022
Details:
IMC-1 (famciclovir) was well-tolerated overall, with only 4.6% of patients dropping out due to adverse events, as compared with 8.1% of placebo treated patients. No adverse event category in the IMC-1 group exceeded a 4% rate with the exception of COVID-19 infection.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
Analysis of gastric mucosa biopsies revealed a significant positive association between actively replicating gastric HSV-1 and multiple functional gastrointestinal disorders, with and without concomitant FM.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Alabama
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. This dual mechanism antiviral therapy is designed to synergistically suppress herpes virus activation and replication.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
IMC-1, a fixed-dose combination of famciclovir and celecoxib, designed to synergistically suppress herpes virus replication, with end goal of reducing virally promoted disease symptom is currently being tested in FORTRESS trial designed to set stage for registrational studies.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
This portfolio of patents also covers the Company’s lead development candidate IMC-1, a synergistic, fixed dose combination of famciclovir and celecoxib, which is in Phase 2b development for the treatment of fibromyalgia.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2021
Details:
The 143-patient Phase 2a trial demonstrated that VIRI’s lead antiviral development candidate, orally administered IMC-1, met its primary endpoint of pain reduction and was statistically better tolerated than placebo.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2021
Details:
IPO funds will allow Virios to complete its Phase IIb, which will assess optimized doses of its antiviral for fibromyalgia, IMC-1, for Phase III, conduct chronic toxicology studies, manufacture more drugs, and prepare a Phase II proof-of-concept study in IBS.
Lead Product(s): Famciclovir,Celecoxib
Therapeutic Area: Musculoskeletal Product Name: IMC-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering December 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
